Market research
CANF Can-Fite BioPharma Ltd
AMEX USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 7M
- P/E ratio
- Not available
- Analyst target
- 8
- Dividend yield
- Not available
- Beta
- -0.04
Profile
Company facts
- Exchange
- AMEX
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US13471N4097
- Market cap
- 7M
- P/E ratio
- Not available
- Analyst target
- 8
- Dividend yield
- Not available
- Beta
- -0.04
About
About Can-Fite BioPharma Ltd
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, It offers cannabinoids for treatment of conditions associated with elevated expression of the A3 adenosine receptors. Further, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CANF discussion.
5 years, 4 months ago
Can-Fite BioPharma Ltd is currently in a long term uptrend where the price is trading 8.2% above its 200 day moving average.
From a valuation standpoint, the stock is 97.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 38.2.
Can-Fite BioPharma Ltd's total revenue sank by 21.9% to $150K since the same quarter in the previous year.
Its net income has dropped by 108.1% to $-4M since the same quarter in the previous year.
Based on the above factors, Can-Fite BioPharma Ltd gets an overall score of 2/5.